- Home
- ZLAB vs ESBA Comparison
ZLAB vs ESBA Comparison
Compare ZLAB & ESBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZLAB
- ESBA
- Stock Information
- Founded
- ZLAB 2013
- ESBA N/A
- Country
- ZLAB China
- ESBA United States
- Employees
- ZLAB N/A
- ESBA N/A
- Industry
- ZLAB Biotechnology: Pharmaceutical Preparations
- ESBA
- Sector
- ZLAB Health Care
- ESBA
- Exchange
- ZLAB Nasdaq
- ESBA NYSE
- Market Cap
- ZLAB 3.0B
- ESBA 2.9B
- IPO Year
- ZLAB 2017
- ESBA 2013
- Fundamental
- Price
- ZLAB $26.91
- ESBA $10.82
- Analyst Decision
- ZLAB Strong Buy
- ESBA
- Analyst Count
- ZLAB 4
- ESBA 0
- Target Price
- ZLAB $52.50
- ESBA N/A
- AVG Volume (30 Days)
- ZLAB 960.6K
- ESBA 10.4K
- Earning Date
- ZLAB 11-12-2024
- ESBA 01-01-0001
- Dividend Yield
- ZLAB N/A
- ESBA 1.27%
- EPS Growth
- ZLAB N/A
- ESBA N/A
- EPS
- ZLAB N/A
- ESBA 0.27
- Revenue
- ZLAB $355,748,000.00
- ESBA $758,432,000.00
- Revenue This Year
- ZLAB $48.50
- ESBA N/A
- Revenue Next Year
- ZLAB $47.37
- ESBA N/A
- P/E Ratio
- ZLAB N/A
- ESBA $40.70
- Revenue Growth
- ZLAB 35.01
- ESBA 4.19
- 52 Week Low
- ZLAB $13.48
- ESBA $7.85
- 52 Week High
- ZLAB $36.60
- ESBA $11.50
- Technical
- Relative Strength Index (RSI)
- ZLAB 45.71
- ESBA 50.44
- Support Level
- ZLAB $25.85
- ESBA $10.80
- Resistance Level
- ZLAB $29.87
- ESBA $11.10
- Average True Range (ATR)
- ZLAB 1.05
- ESBA 0.16
- MACD
- ZLAB -0.18
- ESBA -0.00
- Stochastic Oscillator
- ZLAB 21.98
- ESBA 44.74
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
About ESBA EMPIRE STATE REALTY OP LIM PARTNER
Empire State Realty OP LP is the operating partner of Empire State Realty Inc. The company along with its partner manages, operates, acquires and repositions properties in Manhattan and the greater New York metropolitan area. The firm operates in two segments, Real Estate and Observatory. Through the Real Estate segment, it offers services related to the ownership, management, operation, acquisition, repositioning and disposition of its real estate assets. Under the Observatory segment, it operates the two observatories of the Empire State Building. The company generates maximum revenue from the Real Estate segment.